BOSTAL
GenericsBOSTAL is a generic drug manufacturer focused on Metabolic.
BOSTAL's Key Drugs
BOSTAL's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
BOSTAL's Recent FDA Approvals
New NDA/BLA approvals for BOSTAL over the last two years — novel drugs only, excluding generics and label supplements.
BOSTAL's Therapeutic Areas
BOSTAL's approved drugs and pipeline span 1 therapeutic area, led by Metabolic. Weighted by commercial stage — approved drugs count most, then late-stage trials.
BOSTAL's Top Competitors
BOSTAL's closest competitors by therapeutic-area and drug-target overlap include Merck, Johnson & Johnson, and OTSUKA ICU MEDCL. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
BOSTAL Pipeline Snapshot
BOSTAL has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 1 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Metabolic pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2011-10-21
- Latest
- 2025-08-07
- Applications
- 4